Scoop: Roche scraps one of two schiz­o­phre­nia PhII tri­als af­ter fail­ing the pri­ma­ry end­point

Roche has ter­mi­nat­ed one of two Phase II tri­als test­ing its drug ralmi­taront in pa­tients with schiz­o­phre­nia, the Big Phar­ma con­firmed to End­points News.

The study was ter­mi­nat­ed last month, ac­cord­ing to a June 22 up­date to the reg­istry on clin­i­cal­tri­als.gov. Be­gun in Sep­tem­ber 2020, the tri­al was look­ing at ralmi­taront in pa­tients with acute schiz­o­phre­nia. The tri­al en­rolled 286 pa­tients out of an orig­i­nal­ly planned 308.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.